Cel­gene, Io­n­is ink Chi­na drug de­vel­op­ment pacts; Mo­tif touts pos­i­tive PhI­II an­tibi­ot­ic da­ta

A host of biotech star­tups in Chi­na have been mak­ing the trek to the US to part­ner on promis­ing ex­per­i­men­tal ther­a­pies. And we have news of two new pacts this week:

→ Shang­hai-based An­ten­gene Cor­po­ra­tion inked a col­lab­o­ra­tive part­ner­ship and de­fin­i­tive li­cens­ing agree­ment with Cel­gene Cor­po­ra­tion for its TORC1/TORC2 in­hibitor CC- 223 cov­er­ing Chi­na and oth­er Asian na­tions. An­ten­gene will be ful­ly re­spon­si­ble for the clin­i­cal de­vel­op­ment and com­mer­cial­iza­tion of CC-223 for the de­fined ter­ri­to­ries.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.